Logo image of CRBP

CORBUS PHARMACEUTICALS HOLDI (CRBP) Stock Price, Quote, News and Overview

NASDAQ:CRBP - Nasdaq - US21833P3010 - Common Stock - Currency: USD

7.79  +0.27 (+3.59%)

After market: 7.79 0 (0%)

CRBP Quote, Performance and Key Statistics

CORBUS PHARMACEUTICALS HOLDI

NASDAQ:CRBP (5/2/2025, 8:00:01 PM)

After market: 7.79 0 (0%)

7.79

+0.27 (+3.59%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High61.9
52 Week Low4.64
Market Cap95.27M
Shares12.23M
Float11.01M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)05-05 2025-05-05
IPO10-24 2014-10-24


CRBP short term performance overview.The bars show the price performance of CRBP in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 20 -20 40 -40

CRBP long term performance overview.The bars show the price performance of CRBP in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60

The current stock price of CRBP is 7.79 USD. In the past month the price increased by 58.33%. In the past year, price decreased by -79.91%.

CORBUS PHARMACEUTICALS HOLDI / CRBP Daily stock chart

CRBP Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.33 351.09B
AMGN AMGEN INC 13.55 151.20B
GILD GILEAD SCIENCES INC 13.4 129.08B
VRTX VERTEX PHARMACEUTICALS INC 1728.1 128.84B
REGN REGENERON PHARMACEUTICALS 13.67 65.39B
ARGX ARGENX SE - ADR 341.93 39.67B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 33.74B
ONC BEIGENE LTD-ADR N/A 27.57B
BNTX BIONTECH SE-ADR N/A 25.23B
NTRA NATERA INC N/A 21.30B
SMMT SUMMIT THERAPEUTICS INC N/A 20.72B
BIIB BIOGEN INC 7.81 18.10B

About CRBP

Company Profile

CRBP logo image Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. The company is headquartered in Norwood, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2014-10-24. The firm has a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The Company’s oncology pipeline comprises two experimental drugs targeting solid tumors: CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, and CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFB expressed on cancer cells. CRB-701 is a monoclonal antibody attached to a monomethyl auristatin E (MMAE) cytotoxic payload using a proprietary linker technology. The pipeline also includes CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss.

Company Info

CORBUS PHARMACEUTICALS HOLDI

500 River Ridge Drive

Norwood MASSACHUSETTS 02062 US

CEO: Yuval Cohen

Employees: 28

CRBP Company Website

CRBP Investor Relations

Phone: 16179630103

CORBUS PHARMACEUTICALS HOLDI / CRBP FAQ

What is the stock price of CORBUS PHARMACEUTICALS HOLDI today?

The current stock price of CRBP is 7.79 USD. The price increased by 3.59% in the last trading session.


What is the ticker symbol for CORBUS PHARMACEUTICALS HOLDI stock?

The exchange symbol of CORBUS PHARMACEUTICALS HOLDI is CRBP and it is listed on the Nasdaq exchange.


On which exchange is CRBP stock listed?

CRBP stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for CORBUS PHARMACEUTICALS HOLDI stock?

16 analysts have analysed CRBP and the average price target is 53.15 USD. This implies a price increase of 582.33% is expected in the next year compared to the current price of 7.79. Check the CORBUS PHARMACEUTICALS HOLDI stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is CORBUS PHARMACEUTICALS HOLDI worth?

CORBUS PHARMACEUTICALS HOLDI (CRBP) has a market capitalization of 95.27M USD. This makes CRBP a Micro Cap stock.


How many employees does CORBUS PHARMACEUTICALS HOLDI have?

CORBUS PHARMACEUTICALS HOLDI (CRBP) currently has 28 employees.


What are the support and resistance levels for CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?

CORBUS PHARMACEUTICALS HOLDI (CRBP) has a support level at 7.78 and a resistance level at 7.97. Check the full technical report for a detailed analysis of CRBP support and resistance levels.


Should I buy CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does CORBUS PHARMACEUTICALS HOLDI (CRBP) stock pay dividends?

CRBP does not pay a dividend.


When does CORBUS PHARMACEUTICALS HOLDI (CRBP) report earnings?

CORBUS PHARMACEUTICALS HOLDI (CRBP) will report earnings on 2025-05-05.


What is the Price/Earnings (PE) ratio of CORBUS PHARMACEUTICALS HOLDI (CRBP)?

CORBUS PHARMACEUTICALS HOLDI (CRBP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.66).


What is the Short Interest ratio of CORBUS PHARMACEUTICALS HOLDI (CRBP) stock?

The outstanding short interest for CORBUS PHARMACEUTICALS HOLDI (CRBP) is 19.42% of its float. Check the ownership tab for more information on the CRBP short interest.


CRBP Technical Analysis

ChartMill assigns a technical rating of 3 / 10 to CRBP. When comparing the yearly performance of all stocks, CRBP is a bad performer in the overall market: 93.66% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

CRBP Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to CRBP. CRBP has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

CRBP Financial Highlights

Over the last trailing twelve months CRBP reported a non-GAAP Earnings per Share(EPS) of -3.66. The EPS increased by 63.94% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -25.79%
ROE -28.23%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%56.91%
Sales Q2Q%N/A
EPS 1Y (TTM)63.94%
Revenue 1Y (TTM)N/A

CRBP Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 86% to CRBP. The Buy consensus is the average rating of analysts ratings from 16 analysts.


Ownership
Inst Owners90.43%
Ins Owners1.72%
Short Float %19.42%
Short Ratio9.3
Analysts
Analysts86.25
Price Target53.15 (582.28%)
EPS Next Y-44.39%
Revenue Next YearN/A